Currently, multiple phase 2 and 3 trials are being performed investigating the impact of setmelanotide treatment in patients with obesity from defects in various genes located in the leptin-melanocortin pathway, with the final aim to extend the indication of setmelanotide treatment to a larger group of patients with genetic obesity (NCT05093634, NCT04963231, and NCT04966741). The gene discussed is LEP; the disease is obesity disorder.